Latest news

• Merck suspends two Keytruda trials after patient deaths

  Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.

• Keytruda and Opdivo backed for new uses in Europe

  cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck

• Keytruda claims first blood cancer OK from FDA

  Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light for the drug in a haematological cancer. ... The US regulator gave a conditional approval to Keytruda (pembrolizumab) for cHL

• Opdivo gets green light for Hodgkin lymphoma in Europe

  Less common than non-Hodgkin's lymphoma, cHL affects around 12, 200 people in the EU every year, often being diagnosed in early adulthood. ... BMS says the drug is still showing robust growth in other indications such as melanoma, renal cancer and cHL.

• BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

  The Medicines Healthcare Products and Regulatory Agency (MHRA) approved Opdivo for early access as a monotherapy for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have ... In a recent phase II trial, the